|D003141||Communicable Diseases NIH||0.07|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
There is one clinical trial.
The objective of MoxiCov is to monitor the oximetry of patients admitted to the Covid nursery to provide a more detailed assistance expecting to reduce the amount of hypoxia in these patients.
Description: Determination of the number of valid versus not valid or missed measurements of each participant.Measure: Feasibility of the system: Determination of the number of valid versus not valid or missed measurements Time: 6 months
Description: Time spent with SpO2< 93%, 90% and 85%Measure: Hypoxic burden Time: 6 months
Description: Number of times the oximeter record 3 consecutive measurements of SpO2<90%Measure: Hypoxic alarm Time: 6 months
Description: Measurement of NET PROMOTING SCORE (NPS). This score will show the satisfaction of the healthcare team with the device. This score have a minimum of 0 points and maximum of 32 points.Measure: Satisfaction of the nursing, medical team and patients with the implemented system Time: 6 months
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports